In all studied human cancer cells, RCE-induced dose-dependent decline in Bcl-2 protein expression (Figure 4B) the results significantly compared with both CA drug inhibitors (AZA and CQ) exposed cells and non-treated cancer cells (control) as shown in Figure 4B. As in observation, there was more reduction in the expression of the anti-apoptotic protein Bcl-2 in SKOV3 cells treated with RCE at higher doses of 50 and 100 μg/ml than PC-3 and MCF-7 cells, respectively (Figure 4B). The gene discussed is BCL2; the disease is cancer.